Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

PYPD vs ADXN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PYPD Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 6–1 Matrix Metrics)

PYPD Overall Winner 6-Pillar Tally: PYPD 4 – 1 ADXN (1 Tie) Matrix Metrics: PYPD 6 – 1 ADXN

As of Nov 17, 2026, PolyPid Ltd. (PYPD) is the stronger overall head-to-head candidate over Addex Therapeutics Ltd (ADXN) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). PYPD carries a Unified Composite Score of 31.1/100 (SELL) at $6.43 (N/M Forward P/E, 0.0% operating margin), whereas ADXN carries 30.2/100 (SELL) at $3.75 (N/M Forward P/E, -3130.7% operating margin).

  • Defensive Composite Rating Caution: Although PYPD compares more favorably head-to-head, both PYPD (31.1/100 SELL) and ADXN (30.2/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PYPD vs ADXN
PYPD NASDAQ Head-to-Head Winner
PolyPid Ltd. Ordinary Shares
Surgical & Medical Instruments & Apparatus
$6.43
+4.63% 1D
Market Cap $132.2M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.89β · 59% Vol
Unified Composite Score
31.1 / 100 SELL
Tech 50.0 Fund 27.0 Flow 56.0 Mom 32.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (5.9% over 20 days), RSI 63
RSI-14: 63.2 · SMA20: $5.80 · SMA50: $5.40
ADXN NASDAQ
Addex Therapeutics Ltd American Depositary Shares
Pharmaceutical Preparations
$3.75
-2.09% 1D
Market Cap $7.1M
TTM Revenue $83,069
Forward P/E N/M
Beta / 30D Vol 2.30β · 308% Vol
Unified Composite Score
30.2 / 100 SELL
Tech 3.0 Fund 40.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 55
RSI-14: 54.8 · SMA20: $3.21 · SMA50: $3.21

6-Pillar Scorecard Institutional Category Breakdown (PYPD 4 – 1 ADXN)

Columns: Metric · PYPD · ADXN
1. Valuation Multiples ADXN
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 85.7x
2. Growth & Scale PYPD
Revenue Growth (YoY) +0.0% -72.7%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $83,069
Market Cap $132.2M $7.1M
3. Profitability & Quality PYPD
Gross Margin N/A N/A
Operating Margin 0.0% -3130.7%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -243.6% -150.6%
4. Balance Sheet & Cash Flow PYPD
Cash Generation (TTM) N/A -$2.6M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $5.0M Net Cash $2.18 Book/Sh · -150.6% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning PYPD
Options Structure Phase BREAKOUT UNCLASSIFIED
Current IV / %ile 106.3% (12th %ile) N/A (N/A)
Put/Call OI Skew N/A Thin ADR Chain
OBV Trend / Tech Phase ACCUMULATION · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PYPD (6) vs ADXN (1)
Institutional Metric PYPD ADXN Criterion Row Edge
Market Capitalization
Scale
$132.2M $7.1M Larger Scale PYPD
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% -72.7% Higher Growth PYPD
Operating Margin (TTM)
Profitability
0.0% -3130.7% Higher Margin PYPD
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-243.6% -150.6% Higher ROE ADXN
52-Week Range Position
Momentum
80% ($4–$7) 13% ($3–$12) Stronger Trend PYPD
Beta / 30D Volatility
Risk Regime
0.89β · 59% Vol 2.30β · 308% Vol Lower Realized Risk PYPD
Unified Institutional Score
Composite Signal
31.1 / 100 (SELL) 30.2 / 100 (SELL) Higher Composite PYPD
Trailing 12M Revenue (USD)
Operating Scale
N/A $83,069 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 85.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($5.0M Net Cash) -$2.6M EBITDA ($2.18 Book/Sh · -150.6% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PYPD +0.46 pp
PYPD: +36.33% · ADXN: +35.87%
3M Horizon PYPD +71.88 pp
PYPD: +34.91% · ADXN: -36.97%
6M Horizon PYPD +79.96 pp
PYPD: +35.76% · ADXN: -44.2%
1Y Horizon PYPD +134.98 pp
PYPD: +79.25% · ADXN: -55.73%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PYPD vs ADXN. Trailing 12-month operating profitability (PYPD 0.0% vs ADXN -3130.7%) and valuation multiples (PYPD N/M vs ADXN N/M Forward P/E) are benchmarked directly in Pillar 4 below.

PYPD ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-243.6% · N/M
ADXN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$83,069
Gross MarginN/A
Op. Margin-3130.7%
ROE / Fwd P/E-150.6% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PYPD BREAKOUT
40d in phase · OBV ACCUMULATION
Current IV 106.3%
IV Percentile 12th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact PYPD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ADXN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ADXN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PYPD Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $132.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ADXN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $7.1M market capitalization and -3130.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ PYPD vs ADXN Key Questions & Quantitative Answers

As of Nov 17, 2026, PolyPid Ltd. (PYPD) is the stronger overall head-to-head candidate over Addex Therapeutics Ltd (ADXN) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). PYPD carries a Unified Composite Score of 31.1/100 (SELL) at $6.43 (N/M Forward P/E, 0.0% operating margin), whereas ADXN carries 30.2/100 (SELL) at $3.75 (N/M Forward P/E, -3130.7% operating margin). Defensive Composite Rating Caution: Although PYPD compares more favorably head-to-head, both PYPD (31.1/100 SELL) and ADXN (30.2/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

PYPD leads the Growth & Scale pillar: PYPD posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ADXN at -72.7% YoY revenue growth and +0.0% YoY earnings growth on $83,069 TTM revenue (N/A gross margin, -3130.7% operating margin). On trailing 12-month operating scale, PYPD generates N/A in USD-normalized revenue versus $83,069 for ADXN. In operating R&D and SG&A reinvestment, PYPD deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ADXN.

ADXN screens cheaper on headline valuation multiples. PYPD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ADXN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 85.7x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PYPD (-243.6% ROE) versus ADXN (-150.6% ROE) capital efficiency.

In options market volatility and institutional positioning, PYPD carries 106.3% implied volatility (12th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (0.89β · 59% Vol realized risk). By comparison, ADXN carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.30β · 308% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.